Abbott India Reports Robust Q1 Performance with 11% Revenue Growth
Abbott India Limited announced robust Q1 FY2025 financial results. Revenue increased by 11.6% to ₹1,738.35 crore, while net profit grew 11.5% to ₹365.86 crore. EBITDA rose 14.1% to ₹445 crore, with the EBITDA margin improving to 25.63%. The company also appointed Mr. Darshan Gada as an Additional (Non-Executive) Director, effective August 18, 2025, subject to shareholder approval.

*this image is generated using AI for illustrative purposes only.
Abbott India Limited , a leading pharmaceutical company, has announced strong financial results for the first quarter, showcasing significant growth across key metrics.
Financial Highlights
The company's performance for Q1 demonstrated notable improvements:
Metric | Q1 FY2025 | Q1 FY2024 | YoY Change |
---|---|---|---|
Revenue | ₹1,738.35 | ₹1,557.61 | 11.6% |
Net Profit | ₹365.86 | ₹328.01 | 11.5% |
EBITDA | ₹445.00 | ₹390.00 | 14.1% |
EBITDA Margin | 25.63% | 25.10% | 53 bps |
Revenue Growth
Abbott India's revenue from operations increased to ₹1,738.35 crore, up from ₹1,557.61 crore in the same period last year, marking a robust 11.6% year-over-year growth. This growth reflects the company's strong market presence and effective business strategies.
Profitability
The company's net profit rose to ₹365.86 crore, compared to ₹328.01 crore in the previous year's quarter, representing an 11.5% increase. This improvement in profitability demonstrates Abbott India's ability to manage costs effectively while driving revenue growth.
Operational Efficiency
Abbott India's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) grew to ₹445 crore from ₹390 crore in the previous year, showing a 14.1% increase. The EBITDA margin also improved, rising to 25.63% from 25.10%, indicating enhanced operational efficiency and cost management.
Board Meeting Outcomes
In addition to the financial results, the company's Board of Directors approved the appointment of Mr. Darshan Gada as an Additional (Non-Executive) Director, effective August 18, 2025, subject to shareholder approval.
Mr. Gada brings over 21 years of extensive experience in finance, spanning commercial operations, taxation, supply chain finance, mergers & acquisitions, and strategy. His appointment is expected to contribute to Abbott India's financial planning and strategic growth initiatives.
Conclusion
Abbott India's Q1 results demonstrate the company's ability to deliver strong financial performance and operational improvements. With double-digit growth in revenue and profitability, along with strategic appointments to strengthen its leadership team, Abbott India appears well-positioned for continued success in the pharmaceutical sector.
Historical Stock Returns for Abbott
1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|
+0.99% | +1.67% | -3.00% | +19.49% | +22.96% | +101.99% |